“Safety and Efficacy of Subretinal AAV-CRISPR Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I IIa Dose-Escalation Triall”. 2026. Sriwijaya Journal of Ophthalmology 8 (2): 478-85. https://doi.org/10.37275/sjo.v8i2.137.